Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORI-A-ce001 in Facial Acne Vulgaris
NCT05131373Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in acne vulgaris comparing ORI-A-ce001 Arm with Placebo Arm (2 arms). Primary endpoints: Incidence of solicited and unsolicited local and/or systemic adverse events, Incidence of AEs and serious adverse events at 9 months and 4 more. Started Sep 2021; status: completed.
02
Drugs
ORI-A-ce001
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05131373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131373.